Drug
Crenolanib clinical trials
Also written CP-868,596.
Includes 4 studies of Crenolanib besylate.
- studies test it
- 14
- open now
- 0
- in phase 3
- 4
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2012 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 3
Arog Pharmaceuticals, Inc. (11) · St. Jude Children's Research Hospital (2) · University of Ulm (1)
Often tested with
Tested in the same studies.
Ramucirumab (1) · Paclitaxel (1) · Sorafenib (1) · Fludarabine (1) · Cytarabine (1)
Studies
Open first, then newest update. How each study uses crenolanib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLCompletedPhase 3Arog Pharmaceuticals, Inc.NCT03258931Written as Crenolanib
- Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLCompletedPhase 3Arog Pharmaceuticals, Inc.NCT03250338Written as Crenolanib
- Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsCompletedPhase 2Arog Pharmaceuticals, Inc.NCT01522469Written as Crenolanib Besylate (CP-868,596-26)
- Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsCompletedPhase 2Arog Pharmaceuticals, Inc.NCT02400255Written as Crenolanib besylate
- A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsCompletedPhase 2Arog Pharmaceuticals, Inc.NCT01657682Written as Crenolanib besylate
- Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedPhase 3University of UlmNCT02298166Written as Crenolanib
- Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTStatus unknownPhase 3Arog Pharmaceuticals, Inc.NCT02847429Written as Crenolanib
- Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric AdenocarcinomaCompletedPhase 1Arog Pharmaceuticals, Inc.NCT03193918Written as Crenolanib
- Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene AmplificationCompletedPhase 2Arog Pharmaceuticals, Inc.NCT02626364Written as crenolanib
- A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWithdrawnPhase 2Arog Pharmaceuticals, Inc.NCT03324243Written as Crenolanib
- Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult GliomasTerminatedPhase 2Arog Pharmaceuticals, Inc.NCT01229644Written as Crenolanib (CP-868,596)
- Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA GeneCompletedPhase 2Arog Pharmaceuticals, Inc.NCT01243346Written as Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
- Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedPhase 1St. Jude Children's Research HospitalNCT02270788Written as Crenolanib
- PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade GliomaCompletedPhase 1St. Jude Children's Research HospitalNCT01393912Written as Crenolanib
Given in every arm · 4 — crenolanib is usual care beside what is tested
- Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia PatientsCompletedPhase 1/2Arog Pharmaceuticals, Inc.NCT02400281Written as Crenolanib besylate
- A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 MutationsCompletedPhase 2Arog Pharmaceuticals, Inc.NCT02283177Written as crenolanib
- Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AMLCompletedPhase 1/2Arog Pharmaceuticals, Inc.NCT02626338Written as Crenolanib
- CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid TumorsCompletedPhase 1Arog Pharmaceuticals, Inc.NCT00949624Written as CP-868,596
Codes
What other systems call crenolanib · ClinicalTrials.gg INT006206
- MeSH (NLM) C577197crenolanibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LQF7I567TQCRENOLANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q5184160crenolanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64639CrenolanibOne source FDA
- DrugBank DB11832One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C577197 | crenolanib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LQF7I567TQ | CRENOLANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5184160 | crenolanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64639 | Crenolanib | One source FDA |
| DrugBank | DB11832 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.